LLMpediaThe first transparent, open encyclopedia generated by LLMs

Iodine-131

Generated by GPT-5-mini
Note: This article was automatically generated by a large language model (LLM) from purely parametric knowledge (no retrieval). It may contain inaccuracies or hallucinations. This encyclopedia is part of a research project currently under review.
Article Genealogy
Parent: Fukushima Daiichi Hop 4
Expansion Funnel Raw 76 → Dedup 6 → NER 5 → Enqueued 2
1. Extracted76
2. After dedup6 (None)
3. After NER5 (None)
Rejected: 1 (not NE: 1)
4. Enqueued2 (None)
Similarity rejected: 3
Iodine-131
Iodine-131
SM358 · Public domain · source
NameIodine-131
Mass number131
Half life8.02 days
Decay modesbeta decay, gamma emission
Decay productsXenon-131m, Xenon-131

Iodine-131 is a radioactive isotope of iodine used extensively in nuclear medicine, radiopharmaceuticals, and reactor operations, noted for its beta and gamma emissions and an 8.02-day half-life. Researchers at Brookhaven National Laboratory, clinicians at Mayo Clinic, and regulators at International Atomic Energy Agency have all engaged with its applications and risks, while events at Chernobyl disaster, Three Mile Island accident, and Fukushima Daiichi nuclear disaster highlighted its environmental mobility and public health implications.

Background and nuclear properties

Iodine-131 undergoes beta minus decay producing gamma radiation, a decay scheme characterized in nuclear data compilations by institutions such as National Nuclear Data Center, Los Alamos National Laboratory, and Oak Ridge National Laboratory, and these properties inform shielding guidance from United States Nuclear Regulatory Commission and Health Physics Society. Nuclear structure studies referencing the work of Enrico Fermi, Maria Goeppert Mayer, and Otto Hahn contextualize its place among fission fragments alongside nuclides cataloged by Chart of Nuclides, International Commission on Radiological Protection, and World Health Organization. Its decay energy spectra and branching ratios are tabulated in peer-reviewed compilations from European Atomic Energy Community, Joint European Torus, and academic groups at Massachusetts Institute of Technology, University of Oxford, and Stanford University.

Production and sources

Iodine-131 is produced in significant quantities as a fission product in thermal neutron reactors operated by organizations such as Electricité de France, Tokyo Electric Power Company, and Exelon Corporation, and it is also manufactured for medical use in reactor complexes run by National Research Council (Canada), China National Nuclear Corporation, and Kurchatov Institute. Fallout and environmental releases originating from incidents at Chernobyl disaster, Fukushima Daiichi nuclear disaster, and atmospheric testing overseen historically by United States Department of Energy contributed to global deposition monitored by networks including Comprehensive Nuclear-Test-Ban Treaty Organization, Environmental Protection Agency, and World Meteorological Organization. Medical-grade material is often derived from irradiated tellurium targets processed at facilities affiliated with Bhabha Atomic Research Centre, Idaho National Laboratory, and commercial providers regulated by Food and Drug Administration.

Medical uses and therapies

Iodine-131 is a cornerstone of diagnostic and therapeutic protocols in endocrinology practiced at hospitals like Johns Hopkins Hospital, Cleveland Clinic, and Royal Marsden Hospital, where it treats conditions including hyperthyroidism and differentiated thyroid carcinoma following guidelines from American Thyroid Association, European Association of Nuclear Medicine, and Society of Nuclear Medicine and Molecular Imaging. Therapeutic regimens, dosimetry calculations, and patient management draw on methodologies from researchers associated with Marie Curie Hospital, Memorial Sloan Kettering Cancer Center, and the work of clinicians influenced by William Henry Bragg and Irving Langmuir. Regulatory aspects of radiopharmaceutical distribution and physician training involve agencies such as Medicines and Healthcare products Regulatory Agency, Canadian Nuclear Safety Commission, and Therapeutic Goods Administration.

Environmental behavior and health effects

Iodine-131 exhibits environmental transport through air, water, and food chains studied by teams at National Oceanic and Atmospheric Administration, Pacific Northwest National Laboratory, and United Kingdom Atomic Energy Authority, with bioaccumulation in thyroid tissue prompting health monitoring by Centers for Disease Control and Prevention, Public Health England, and International Atomic Energy Agency. Epidemiological assessments linking exposure to thyroid disease and cancer have been conducted by researchers associated with World Health Organization, National Institutes of Health, and the United Nations Scientific Committee on the Effects of Atomic Radiation, while cohort studies following populations affected by Chernobyl disaster and Fukushima Daiichi nuclear disaster inform screening policies from World Health Organization and national ministries such as Ministry of Health (Japan) and Ministry of Health and Family Welfare (India). Food safety interventions developed by Food and Agriculture Organization and European Food Safety Authority address contamination in milk and leafy vegetables through interventions used historically in regions administered by Allied occupation of Japan and emergency responses coordinated with United Nations agencies.

Detection, measurement, and safety protocols

Detection of Iodine-131 employs gamma spectrometry, thyroid probes, and whole-body counters supplied by manufacturers and laboratories like Canberra Industries, ORTEC, and research groups at Brookhaven National Laboratory, with calibration standards provided by National Institute of Standards and Technology and measurement protocols endorsed by International Atomic Energy Agency. Occupational and public safety limits, thyroid blocking strategies using stable potassium iodide, and emergency planning frameworks are promulgated by International Commission on Radiological Protection, United States Environmental Protection Agency, and national bodies such as Health Canada and Australian Radiation Protection and Nuclear Safety Agency. Waste management, decontamination, and long-term monitoring draw on lessons from remediation projects at sites managed by Hanford Site, Sellafield, and recovery efforts coordinated with European Commission initiatives.

Historical incidents and regulatory response

Major releases and their regulatory aftermath include responses to the Chernobyl disaster, where international collaboration led by International Atomic Energy Agency and United Nations Scientific Committee on the Effects of Atomic Radiation reshaped safety norms, and the Fukushima Daiichi nuclear disaster, which prompted reviews by national bodies such as Nuclear Regulation Authority (Japan) and reforms influenced by reports from World Health Organization and International Atomic Energy Agency. Earlier events like the Three Mile Island accident influenced emergency preparedness policies adopted by Nuclear Energy Agency and national regulators including Nuclear Regulatory Commission, while atmospheric testing episodes overseen by United States Department of Defense and Soviet Union signaled the need for monitoring networks such as that established under the Comprehensive Nuclear-Test-Ban Treaty Organization.

Category:Radioisotopes